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Background/aim: FloTrac/Vigileo is a noncalibrated arterial pressure waveform analysis for cardiac index (CI) monitoring. The aim of
our study was to compare the CI measured by the 4th generation of FloTrac with PiCCO in septic shock patients.
Materials and methods: We simultaneously measured the CI using FloTrac (CIv) and compared it with the CI derived from
transpulmonary thermodilution (CItd) as well as the pulse contour-derived CI using PiCCO (CIp).
Results: Thirty-one septic shock patients were included. The CIv correlated with CItd (r = 0.62, P < 0.0001). The Bland-Altman analysis
showed a bias of 0.14, and the limits of agreement were –1.62–1.91 L/min/m2 with a percentage error of 47.4%. However, the concordance
rate between CIv and CItd was 93.6%. The comparison of CIv with CIp (n = 352 paired measurements) revealed a bias of -0.16, and the
limits of agreement were –1.45–1.79 L/min/m2 with a percentage error of 44.8%. The overall correlation coefficient between CIv and CIp
was 0.63 (P < 0.0001), and the concordance rate was 85.4%.
Conclusion: The 4th generation of FloTrac has not acceptable agreement to assess CI; however, it has the ability to tracked changes of
CI, when compared with the transpulmonary thermodilution method by PiCCO.
Key words: Cardiac output, hemodynamic monitoring, pulse contour analysis, arterial waveform analysis, measurement technique

1. Introduction
The cardiac index (CI) is recommended as one of the most
important hemodynamic variables for the assessment of
cardiac function, and guidance of therapy in critically
ill patients within an intensive care unit (ICU) [1]. The
measurement of CI, via the pulmonary artery catheter
(PAC), is presently the standard method; however, the
data of increasing morbidity [2, 3] associated with its
use has intensified the development of a less invasive
device for advanced cardiac monitoring. For instance,
transpulmonary thermodilution as implemented in the
PiCCO device has been developed [4]. Previous studies
showed that CI measured by this device is comparable
with that by the PAC [5–7]. However, this device required
initial calibration to access the hemodynamic parameters
[8].
The noncalibrated arterial pressure waveform analysis
(FloTrac/Vigileo, Edwards Lifescience, Irvine, CA,
USA) has been proposed for continuous CI monitoring.
This device is widely used for monitoring critically ill
patients in operating rooms and ICUs, due to being
less invasive and without needing external calibration.

However, the reliability of CI measured by this device has
had conflicting results. Some studies presented that CI
obtained by the FloTrac is reliable as CI measured by PAC
[9,10]; in contrast, other studies have revealed a limited
correlation, or agreement with other reference CI devices
[4,11,12], especially during hyperdynamic states [13,14]
or hemodynamic instability [15,16]. So, the software of
FloTrac was regularly updated for improved performance
of this device. The 3rd generation software is able to
recognize many hyperdynamic and vasoplegia conditions,
even though the accuracy and tracking ability of this version
are still controversial [17–20]. Recently, the 4th generation
of FloTrac software extended the autocalibration factor to
adjust for acute changes in the systemic vascular resistance
(SVR). Previous literatures reported the 4th generation
of FloTrac had been significantly improved in its ability
to track the changes in CI induced by phenylephrine or
increased vasomotor tone compared with the previous
version [21,22]. In contrast, some studies presented
that the 4th generation of FloTrac still lacks accuracy
along with trending ability in cardiac surgical patients
[23,24]. However, the validation of CI measured by the
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4th generation of FloTrac has been limited evaluation for
septic shock patients.
Thus, the aim of our study was to validate the
accuracy of the 4th generation of FloTrac with the PiCCO
(transpulmonary thermodilution and pulse contour
analysis) as a reference technique in patients with septic
shock. The secondary aim was to determine the tracking
ability in CI obtained by the latest version of FloTrac,
induced by either increasing the dosage of norepinephrine
or fluid bolus therapy.
2. Material and methods
2.1 Patients
This prospective study was conducted in the Medical
Intensive Care Unit of Songklanagarind Hospital, Prince
of Songkla University, Thailand. It was approved by the
Institutional Human Research Ethics Committee (HREC)
(54-042-14-1-2), and informed written consents were
obtained from the next of kin of each patient. Subjects
were informed as soon as their mental status allowed, and
the possibility was given for them to withdraw from the
study.
The inclusion criteria were as follows: 1. Having
septic shock, as defined by the Sepsis–3 definition [25];
2. Existence of a central venous catheter. The patients
were excluded if they had intracardiac shunts and cardiac
arrhythmias (atrial fibrillation or frequent premature
beats), due to impaired reliability of the transpulmonary
thermodilution method and pulse contour analysis.
2.2 Study protocol
For all patients, the PiCCO 5 French 20 cm arterial
thermistor catheter (Pulsiocath PV2015L20, Pulsion
Medical Systems, Munich, Germany) was inserted into
the femoral artery. The arterial line was divided into 2
branches, 1 connected to the Philips CCO/CO module
(model M10212A, Philips Medical Systems, Böblingen,
Germany) with the PiCCO software integrated into
the patient’s monitor, Philip IntelliVue MP70 (CMS
monitor model M1097A, software version 17.62, Philips
Medical Systems), and the other branch connected to a
FloTrac/Vigileo device (FloTrac version 04.00, Edwards
Lifesciences, Irvine, CA, USA). This enabled the 2
devices to analyze the same arterial pressure waveform
simultaneously.
The FloTrac analyzed the arterial pressure waveform
100 times/s over 20 s. The stroke volume (SV) was based
on the contribution of pulse pressure relative to SV,
which is the proportion of pulse pressure to the standard
deviation of arterial pulse pressure (APsd). The device
calculated SV as APsd × X, where X compensates for
differences in vascular compliance and resistance. In the
4th generation of FloTrac, X is calculated as K4 × Kfast. Kfast
is inversely proportional to arterial pressure and calculated

every 20 s. K4 uses multivariate polynomial equations of
waveform variables such as skewness and kurtosis and is
averaged every minute [21,22]. At the beginning of each
data recording session, the Vigileo monitor was initialized
by entering the patient’s characteristics (sex, age, weight,
and height), along with zeroing the FloTrac sensor against
atmospheric pressure.
Hemodynamic measurements included recording of
heart rate (HR), arterial blood pressure, central venous
pressure (CVP), transpulmonary thermodilution CI
(CItd), pulse contour CI (CIp), FloTrac/Vigileo CI (CIv),
systemic vascular resistance index (SVRI), and other
transpulmonary hemodynamic variables. The CItd was
measured by the Philips CCO/CO device by injecting
15 mL of iced saline (<8 °C) through the central venous
catheter.
The CItd was calculated using the following equation:
CItd = Vi × (Tb-Ti) × k/AUC ÷ BSA
When Vi is the injected volume, Tb is blood temperature,
Ti is injected temperature, k is a constant proportional to
the specific weights and specific heat of blood and injected,
AUC is the area under the transpulmonary thermodilution
curve and BSA is body surface area [26].
The injection was manually performed in triplicate, and
the values of CItd were averaged. The CItd was repeated
every 8 h for 48 h.
The CIp was estimated by the following equation:
CIp = cal × HR × × dt ! 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 )

P(t)
dP
+ C(p) × 6
SVR
dt

When cal is the patient specific calibration factor
P(t)
dP
determined with thermodilution,
is C(p)
area ×
under6 the
! 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 )
+
SVR
dt
P(t)
dP
pressure!curve,
C(p)
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
+ C(p) × 6is shape of pressure
) is compliance,
SVR
dt
curve.
We used the values of CIp and CIv that were
automatically displayed on the screens of both devices.
The CIv and CIp were recorded every 2 h over a period of
48 h, after study initiation.
We evaluated the tracking trends in CIv compared
with CIp induced by either increasing the dosage of
norepinephrine (n = 56), or fluid bolus (n = 16) in the
subgroups of septic shock patients. Hemodynamic data
were collected before and after therapeutic interventions
(at 5 min after increase norepinephrine or at the end of
fluid bolus).
2.3 Statistical analysis
The normal distribution of data was tested by the ShapiroWilk test. The correlation was assessed by Pearson’s
coefficient. The level of agreement as well as bias between
the methods were evaluated by Bland-Altman analysis
and corrected with repeated measurement [27]. The
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percentage errors were calculated as: 1.96 times of standard
deviation of the bias divided by the mean CI of reference
methods [19,20,28,29]; a percentage error less than 45%
was considered clinically acceptable [30,31]. The trending
ability of CI was assessed by 4-quadrant plot analysis,
with an exclusion zone of 10% [22]. For this method, the
concordance rate was defined as the proportion of the
number of paired CI change, with the same direction of
changes in both methods, which were presented in the
upper right and lower left quadrant. A concordance rate
of more than 90% was defined as an acceptable value
[32]. In addition, we analyzed significant influence on
bias between CIv and CItd, using a linear mixed effect
model for repeated measurements. Mean arterial pressure
(MAP), SVRI, and norepinephrine dose were treated as
fixed effects while each patient was treated as a random
effect. Comparisons between subjects receiving fluid
bolus and an up dose of norepinephrine were performed
by a 2–tailed Student t test or Mann-Whitney U test, as
appropriate. We compared the relative changes of CIv with
those of CIp during the therapeutic intervention by the
Bland-Altman analysis and correlation analysis. A receiver
operating characteristic (ROC) curve was used to assess
the ability of CIv to detect concordant and significant CIp
≥ 15%, after both interventions. A 2–sided P value < 0.05
was considered statistically significant. Statistical analysis
was performed by Stata software version 11.
3. Results
Thirty-one mechanically ventilated septic shock patients
were enrolled in our study. Patient characteristics
are summarized in Table 1. All patients received
norepinephrine administration and 13 patients (41.9%)
were treated with combined vasoactive agents at the time
of inclusion in our study.
3.1 Comparison between CIv and CItd
There were 156 paired CI measurements obtained to
compare between CIv and CItd. CIv and CItd ranged
from 1.5–6.8 and 1.5–6.9 L/min/m2 respectively. The CIv
was significantly correlated with CItd with r = 0.62 (P <
0.0001) (Table 2). Bland-Altman analysis showed that bias
along with limits of agreement was 0.14 and –1.62–1.91
L/min/m2 with the percentage error being 47.4% (Figure
1). Figure 2 presents the 4–quadrant plot analysis between
CIv and CItd, which has an acceptable concordance rate of
93.6%. The bias of CIv and CItd was correlated with SVRI
(r = -0.46, P < 0.0001). The linear mixed effect model for
repeated measurements, showed that the bias between CIv
and CItd was influenced only by SVRI (P < 0.001).
3.2 Comparison of CIv with CIp
A total of 352 paired CI measurements were obtained,
so as to compare between the 2 methods. CIv ranged
from 1–6.2, while CIp ranged from 1.4–6.9 L/min/m2.
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Table 1. Patients clinical characteristic (n = 31)
Men, n (%)

17 (54.8)

Age (years)

56.3 ± 18.5

Body weight (kg)

60.6 ± 10.1

Height (cm)

161.8 ± 8.2

Body surface area (kg/m2)

1.64 ± 0.16

APACHE II

26.5 ± 8.1

SOFA

9.8 ± 3.7

ICU length of stay (days)

7.7 ± 5.4

Community acquired infection, n (%)

20 (64.5)

Site of infection, n (%)
- Respiratory tract infection

13 (41.9)

- Digestive system

7 (22.6)

- Primary bacteremia

4 (12.9)

- Others*

7 (22.5)

Combined vasoactive, n (%)

13 (41.9)

Norepinephrine (ug/kg/min)

0.33 ± 0.18

Dopamine (ug/kg/min)

11.5 ± 10.3

APACHE, acute physiology and chronic health evaluation; ICU,
intensive care unit; SOFA, sequential organ failure assessment
*Others, skin and soft tissue (2), urinary tract (2), surgical site
(1), bone and joint (1), unknown (1).

A significant correlation was observed between CIv and
CIp (r = 0.63, P < 0.0001) (Table 2). The Bland-Altman
corrected, for repeated measurements, showed bias of
–0.16 and limits of agreement were –1.45–1.79 L/min/m2
with a percentage error of 44.8% for CIv and CIp (Figure
3). The concordance rate between CIv and CIp was 85.4%
(Figure 4).
3.3 Comparison of CIv and CIp in subjects with an
increased dose of norepinephrine
There were 56 hemodynamic data (30 patients) obtained
before and after an increase in norepinephrine infusion.
After increasing the dosage of norepinephrine, HR, blood
pressure, CVP, CIv, and CIp were significantly increased,
while SVRI and SVV were significantly decreased (Table
3). The bias and limits of agreement between the absolute
changes in CIv and CIp, induced by increasing the dosage
of norepinephrine were –0.47 and –1.73– 0.8 L/min/m2.
The coefficient of correlation coupled with concordance
rate between the percent changes in CIv and in CIp was
0.8 (P < 0.0001) and 95.8% respectively. An increase in
CIv ≥ 17.5% detected an increase in CIp (≥ 15%), after
an increased dose of norepinephrine with a sensitivity of
89.7% and specificity of 70.4% (AUC 0.847, 95%CI 0.743–
0.952) (Figure 5).
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Table 2. Summary of the comparison between cardiac index measured by the 4th generation of FloTrac with PiCCO.
Correlation, r

Bias
(L/min/m2)

Limits of agreement
(L/min/m2)

Percentage
error (%)

Concordance (%)

CIv-CItd (n = 156)

0.62

0.14

–1.62–1.91

47.4

93.6

CIv-CIp (n = 352)

0.63

-0.16

–1.45–1.79

44.8

85.4

CIv, cardiac index obtained by FloTrac.
CItd, cardiac index measured by transpulmonary thermodilution of PiCCO.
CIp, cardiac index measured by pulse contour analysis of PiCCO.

Figure 1. Bland-Altman plot for CIv and CItd. Straight line indicating mean bias, dash line indicating 95% limit of agreement CIv,
cardiac index obtained by FloTrac; CItd, cardiac index measured by transpulmonary thermodilution of PiCCO.

Figure 2. Four-quadrant plot analysis to determine the trending ability for percentage change of CIv against CItd. Central square
is an exclusion zone (% change < 10%); CIv, cardiac index obtained by FloTrac; CItd, cardiac index measured by transpulmonary
thermodilution of PiCCO.
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Figure 3. Bland-Altman plot for CIv and CIp. Straight line indicating mean bias,
dash line indicating 95% limit of agreement CIv, cardiac index obtained by FloTrac;
CIp, cardiac index measured by pulse contour analysis of PiCCO.

Figure 4. Four-quadrant plot analysis to determine the trending ability for percentage
change of CIv against CIp. Central square is an exclusion zone (% change <10%) CIv,
cardiac index obtained by FloTrac; CIp, cardiac index measured by pulse contour
analysis of PiCCO.

3.4 Comparison of CIv and CIp in subjects with receiving
fluid bolus
A total of 16 hemodynamic measurements (11 patients)
were performed before and after saline 500 mL bolus
over 30 min. MAP, CIv, and CIp significantly increased
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by 10%, 14.5%, and 10.3% respectively (Table 4). The bias
and limit of agreement between absolute changes in CIv
and CIp induced by volume expansion were 0.05 and
–0.28 to 0.38 L/min/m2. The coefficient of correlation and
concordance rate between the percent changes in CIv and
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Table 3. Hemodynamic parameters before and after increase dose of
norepinephrine (n = 56).
Before

After

P value

HR (/min)

105.9 ± 24.9

115.4 ± 27.2

< 0.001

SBP (mmHg)

104 (98–113)

123.5 (110.25–140)

< 0.001

DBP (mmHg)

55 (52–62)

66.5 (61–70.75)

< 0.001

MAP (mmHg)

68.4 ± 8.5

86.5 ± 11.0

< 0.001

CVP (mmHg)

14 (12–16.7)

15 (13–18)

< 0.001

SVRI (dyne-s-m /cm )

1,530.3 ± 410.6

1,508.3 ± 453.2

<0.001

CIv (L/min/m2)

3.2 ± 0.7

3.9 ± 0.8

< 0.001

CIp (L/min/m )

3.4 ± 0.9

3.9 ± 0.8

0.003

SVV (%)

13 (7–22.2)

9.5 (6.2–19)

0.04

NE (ug/kg/min)

0.20 ± 0.16

0.27 ± 0.17

< 0.001

2

2

5

CIv, cardiac index obtained by FloTrac; CIp, cardiac index measured by pulse
contour analysis of PiCCO; CVP, central venous pressure; DBP, diastolic blood
pressure; HR, heart rate; MAP, mean arterial pressure; NE, norepinephrine; SBP,
systolic blood pressure; SVRI, systemic vascular resistance index; SVV, stroke
volume variation.

Figure 5. Receiving operating characteristic curves for the changes in CIv to detect an
increase in CIp ≥ 15% induced by increase dose of norepinephrine. CIv, cardiac index
obtained by FloTrac; CIp, cardiac index measured by pulse contour analysis of PiCCO.

in CIp induced by fluid expansion were 0.49 (P = 0.05)
and 83% respectively. An increase in CIv ≥ 13% detected
an increase in CIp (≥ 15%) induced by fluid bolus with
a sensitivity of 75% and specificity of 66.7% (AUC 0.823,
95%CI 0.574–1) (Figure 6).

4. Discussion
Our results found that the 4th generation of FloTrac has
no clinically acceptable agreement to estimate CI, but
correctly tracked changes in CI when compared with
transpulmonary thermodilution method by PiCCO.
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Table 4. Hemodynamic parameters before and after volume expansion (n = 16).
Before

After

P-value

HR (/min)

107.9 ± 24.2

104.6 ± 23.3

0.01

SBP (mmHg)

100.6 ± 22.5

110.6 ± 23.8

< 0.001

DBP (mmHg)

54 ± 8.6

57 ± 9.3

< 0.001

MAP (mmHg)

67.9 ± 13.4

75.6 ± 14.5

< 0.001

CVP (mmHg)

13.7 ± 3.1

15.2 ± 3.8

0.05

SVRI (dyne-s-m /cm )

1,728.1 ± 884.7

1,817.6 ± 965.9

0.29

CIv (L/min/m2)

2.7 ± 0.9

3.1 ± 0.9

0.0001

CIp (L/min/m )

2.9 ± 1.1

3.2 ± 1.0

0.003

SVV (%)

18.5 ± 8.0

15.1 ± 8.2

0.06

2

2

5

CIv, cardiac index obtained by FloTrac; CIp, cardiac index measured by pulse
contour analysis of PiCCO; CVP, central venous pressure; DBP, diastolic blood
pressure; HR, heart rate; MAP, mean arterial pressure; NE, norepinephrine; SBP,
systolic blood pressure; SVRI, systemic vascular resistance index; SVV, stroke
volume variation.

Figure 6. Receiving operating characteristic curves for the changes in CIv to detect
an increase in CIp ≥ 15% induced by fluid loading. CIv, cardiac index obtained by
FloTrac; CIp, cardiac index measured by pulse contour analysis of PiCCO.

In addition, the 4th generation of FloTrac also has the
ability to track changes of CI compared with pulse
contour analysis by PiCCO when they are induced by
norepinephrine administration.
Persistent or reoccurring shock, after initial
resuscitation, is both an indication and recommendation
for the monitoring of CI in critically ill patients [1]. Several
different techniques are available to monitor CI. The
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choice of CI monitoring methods in individual critically
ill patients depends on many factors such as patient
condition, hemodynamic monitoring requirement, and
monitoring the response to therapeutic interventions.
Noncalibrated pulse contour analysis such as FloTrac/
Vigileo, is one of the most popular used CI monitoring
method for critically ill patients. Similar with our study,
several studies showed that CI obtained by previous version
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of FloTrac had no acceptable agreement with the percentage
error of 49–61%, when compared with transpulmonary
thermodilution by PiCCO, [13–16]. Boettger et al. reported
the bias of 0.72 L/min and limits of agreement of -2.16–3.6
L/min between FloTrac and thermodilution by PiCCO, and
also demonstrated that FloTrac underestimation at high
cardiac output but an overestimation at low cardiac output
relative to transpulmonary thermodilution by PiCCO
in septic patients [14]. Slagt et al. compared CI derived
by the 3rd generation of FloTrac with transpulmonary
thermodilution by VolumeView/EV1000 in sepsis patients
[29]. They found moderate agreement between the two
methods, with a percentage error of 48%, with poor to
moderate CI tracking abilities. Moreover, the 3rd generation
of FloTrac has a moderate ability to track changes in CI
when compared with the thermodilution method [18,19].
The algorithm of FloTrac software was updated for
improved performance of this device. The latest is the 4th
version, and Kfast is the newly added component for faster
response to the changes of the vascular tone. Two previous
studies found that the performance along with trending
ability of the 4th generation of FloTrac was improved after
phenylephrine bolus compared with 3rd software in cardiac
surgical patients [21,22]. Nevertheless, in one study the
percentage error was higher than the clinically acceptable
range (55.4%), due to bias having been correlated with the
SVRI [22]. Similar, with our study in septic shock patients,
the bias between CIv and CItd was strongly associated with
SVRI. Moreover, bias of the 4th generation of FloTrac was
still influenced by SVRI much the same as in the previous
version. Therefore, the FloTrac software has room for
improvement in the performance of its software.
Validation of CI monitoring devices should not only
be based on its ability to measure absolute CI values,
but also on their ability to track trending changes of CI.
Serial changes in CI also provide valuable information to
intensivists to allow them to cope with critical conditions
and make adjustment to the therapeutic treatment. The
ability of the 3rd of FloTrac software to rapidly detect
CI changes has been reported in septic shock patients.
Monnet et al. showed that the 3rd generation of FloTrac has
moderate reliability for tracking changes in CI induced by
fluid expansion and norepinephrine administration [19].
However, in our study, for the 4th generation of FloTrac,
it demonstrated the reliability in following the changes
in CI, and changes in CI induced by norepinephrine
administration. This study presented the relatively high
correlation coefficients between the changes in CIv and
CIp, via high concordance rates. This demonstrated that
the 4th generation of the FloTrac algorithm appears to
have improvements in its tracking ability compare to the
previous version.
While the accuracy of the 4th generation of FloTrac
has been evaluated in patients undergoing cardiac
surgery, our study is the first validation of the updated

FloTrac software in septic shock patients. However,
some limitations of our study should be taken into
consideration. First, we compared the 4th generation of
FloTrac with transpulmonary thermodilution using this
as a reference method. Several studies have shown that the
transpulmonary thermodilution by PiCCO provides just as
a reliable estimation of CI as the thermodilution method
by PAC [5–7], even though it is not the gold standard or
a perfect CI method. Second, we validated the trending
ability of CI by FloTrac utilizing only pulse contour
analysis obtained by PiCCO when increasing dosage of
norepinephrine or fluid bolus, because the hemodynamic
instability of our septic shock patients is limited to
performed thermodilution method. Monnet et al. found
that neither CIp nor its tracking ability for the changes
of CI induced by volume expansion and norepinephrine
administration, when compared with transpulmonary
thermodilution by PiCCO for septic shock patients was
reliable and accurate [13]. Finally, we used a percentage
error of 45% as clinically acceptable, which differs from
previous references of 30%. This percentage error was
suggested by Critchley and Critchley in a metaanalysis
paper published in 1999 based on precision for the
reference method of ± 20% [33]. However, the precision
of CI measurement can vary with the use of different
techniques. Recent, metaanalysis of accuracy and precision
of CI monitoring in critically ill patients presented that
none of the 4 minimally invasive CI measurements met
the criteria for acceptability of agreement, as suggested
by Critchley and Critchley [30]. Therefore, they suggested
that the percentage error in agreement of 45% represents
a more realistic achievable precision in clinical practice
[11,30]. However, the percentage errors of 4th generation of
FloTrac in our study remain beyond the revised boundary
for septic shock patients.
In conclusion, the 4th generation of FloTrac has
not clinically acceptable agreement to assess CI, when
compared with the transpulmonary thermodilution
method by PiCCO. However, the tracking ability of the
last updated version of FloTrac is reasonable for clinically
relevant changes in CI and demonstrated good reliable for
assessing the CI changes induced by norepinephrine.
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